# Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

> **NCT06659705** · PHASE2 · RECRUITING · sponsor: **Institut Curie** · enrollment: 35 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **DRUG:** 68Ga-FAPI-46 for PET / CT scan

## Key facts

- **NCT ID:** NCT06659705
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2029-08-04
- **Final completion:** 2030-08-08
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06659705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06659705, "Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06659705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*